Immuno-chemo vs chemo before surgery for limited SCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding immunotherapy (PD-L1/PD-1 inhibitors) to standard chemotherapy before surgery helps people with limited-stage small cell lung cancer. The goal is to see if the combination shrinks the tumor more effectively than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have limited-stage small cell lung cancer (cancer only in one lung and nearby nodes, not spread outside the chest).
- You are between 18 and 75 years old.
- You have not had any treatment for small cell lung cancer before (no chemo or radiation).
- You are healthy enough for major surgery, with adequate organ function (kidneys, liver, blood counts).
- You have not had immunotherapy or certain other medical conditions like autoimmune disease, serious heart problems, or lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
This Phase 3 trial tests whether adding a drug called adebrelimab (SHR-1316) to standard chemotherapy before treatment leads to more successful surgery and/or radiation for limited-stage small cell lung cancer. It’s for people who have not had any prior cancer treatment and can undergo planned “curative” treatment after 4 cycles.
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
This trial combines standard chemotherapy and radiation with two immunotherapy drugs (immune checkpoint inhibitors) to see if they work better together for people with limited-stage small cell lung cancer. It aims to improve outcomes without using strong immune-suppressing medicines.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.